शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
LUPINNSELupin Limited· Pharmaceuticals & BiotechnologyHighPositive
Announced Fri, 27 Feb, 2026 · 13:00 IST

Lupin gets US FDA EIR with VAI classification for Goa facility

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.9%Reaction day
₹2316.70
prior close
₹2307.00
announcement price
In-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.1%+0.2% vs market
Pharmaceuticals peers, median of 157sector-1.0%+0.1% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.1
10m
+0.5
15m
+0.6
30m
+0.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.9-1.1+0.2-1.0+0.1
Next day
+0.0-2.8+2.8-2.5+2.6
2d
-0.4-4.9+4.5-3.9+3.5
3d
+0.9-3.4+4.3-3.0+3.9
4d
+0.6-4.1+4.7-3.0+3.6
5d
-0.7-6.1+5.3-4.0+3.2
1w
+0.9-5.6+6.5-2.8+3.7
15d
-1.2-12.0+10.8-9.7+8.6
1m
+0.7-9.7+10.3-8.8+9.5
2m
+0.1+0.5-0.4+2.4-2.3
3m
-1.8+3.6-5.4+7.9-9.7
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin received an Establishment Inspection Report (EIR) from the US FDA for its Goa facility with a satisfactory Voluntary Action Indicated (VAI) classification. The inspection took place from November 10 to November 21, 2025. VAI classification means no official action is required, reflecting positively on quality and compliance standards. MD Nilesh Gupta called it a sign of continued focus on quality excellence.

Likely market impact

Positive signal for regulatory compliance and US market operations; supports investor confidence in Lupin's manufacturing quality.